These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29448851)

  • 1. Salvage tigecycline in high risk febrile neutropenic patients with hematological malignancies: a prospective multicenter study.
    Zhou XP; Ye XJ; Shen JP; Lan JP; Jiang HF; Zhang J; Zhang XJ; Li L; Qian SX; Tong HY
    Leuk Lymphoma; 2018 Nov; 59(11):2679-2685. PubMed ID: 29448851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tigecycline as salvage treatment of febrile neutropenia in patients with haematological malignancies-a retrospective single-centre analysis of 200 cases.
    Geßner D; Berisha M; Esser T; Schalk E
    Ann Hematol; 2023 Sep; 102(9):2607-2616. PubMed ID: 37186157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode.
    Demirel A; Tabak F; Ar MC; Mete B; Öngören Ş; Yemişen M; Özaras R; Eşkazan E; Başlar Z; Mert A; Soysal T; Ferhanoğlu B; Aydın Y; Öztürk R
    Turk J Haematol; 2015 Sep; 32(3):243-50. PubMed ID: 25913035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between mortality and microbiological parameters in febrile neutropenic patients with hematological malignancies.
    Calik S; Ari A; Bilgir O; Cetintepe T; Yis R; Sonmez U; Tosun S
    Saudi Med J; 2018 Sep; 39(9):878-885. PubMed ID: 30251730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary experience of tigecycline treatment for infection in children with hematologic malignancies.
    Lin S; Zhang C; Ye S
    Int J Clin Pharm; 2018 Oct; 40(5):1030-1036. PubMed ID: 30051224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study.
    Jeong SH; Kim DY; Jang JH; Mun YC; Choi CW; Kim SH; Kim JS; Park JS
    Ann Hematol; 2016 Jan; 95(2):337-44. PubMed ID: 26596974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitals.
    Schwab KS; Hahn-Ast C; Heinz WJ; Germing U; Egerer G; Glasmacher A; Leyendecker C; Marklein G; Nellessen CM; Brossart P; von Lilienfeld-Toal M
    Infection; 2014 Feb; 42(1):97-104. PubMed ID: 23979853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia.
    Bucaneve G; Micozzi A; Picardi M; Ballanti S; Cascavilla N; Salutari P; Specchia G; Fanci R; Luppi M; Cudillo L; Cantaffa R; Milone G; Bocchia M; Martinelli G; Offidani M; Chierichini A; Fabbiano F; Quarta G; Primon V; Martino B; Manna A; Zuffa E; Ferrari A; Gentile G; Foà R; Del Favero A
    J Clin Oncol; 2014 May; 32(14):1463-71. PubMed ID: 24733807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial.
    Oyake T; Kowata S; Murai K; Ito S; Akagi T; Kubo K; Sawada K; Ishida Y
    Eur J Haematol; 2016 Jun; 96(6):602-9. PubMed ID: 26216048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended vs Bolus Infusion of Broad-Spectrum β-Lactams for Febrile Neutropenia: An Unblinded, Randomized Trial.
    Ram R; Halavy Y; Amit O; Paran Y; Katchman E; Yachini B; Kor S; Avivi I; Ben-Ami R
    Clin Infect Dis; 2018 Sep; 67(8):1153-1160. PubMed ID: 29608680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
    Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
    Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of time to antibiotics and clinical outcomes in adult hematologic malignancy patients with febrile neutropenia.
    Butts AR; Bachmeier CC; Dressler EV; Liu M; Cowden A; Talbert J; Adams VR
    J Oncol Pharm Pract; 2017 Jun; 23(4):278-283. PubMed ID: 28077045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Therapeutic Drug Monitoring Optimizes Teicoplanin Use in Febrile Neutropenic Patients with Hematological Malignancies.
    Wang YW; Hou HA; Lin CC; Lin HY; Chen PZ; Kuo CH; Chiu HH; Chuang CC; Chen YJ; Lin SW
    Adv Ther; 2024 Jul; 41(7):2966-2977. PubMed ID: 38743241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the efficacy of piperacillin-tazobactam and cefoperazone-sulbactam therapies in the empirical treatment of patients with febrile neutropenia.
    Aynioglu A; Mutlu B; Hacihanefioglu A
    Rev Esp Quimioter; 2016 Apr; 29(2):69-75. PubMed ID: 26888338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Success rate and risk factors for failure of empirical antifungal therapy with itraconazole in patients with hematological malignancies: a multicenter, prospective, open-label, observational study in Korea.
    Kim SJ; Cheong JW; Min YH; Choi YJ; Lee DG; Lee JH; Yang DH; Lee SM; Kim SH; Kim YS; Kwak JY; Park J; Kim JY; Kim HG; Kim BS; Ryoo HM; Jang JH; Kim MK; Kang HJ; Cho IS; Mun YC; Jo DY; Kim HY; Park BB; Kim JS
    J Korean Med Sci; 2014 Jan; 29(1):61-8. PubMed ID: 24431907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal Trough Concentration of Teicoplanin in Febrile Neutropenic Patients with Hematological Malignancy.
    Sato Y; Hiramatsu K; Suzuki Y; Tanaka R; Kaneko T; Nonoshita K; Ogata M; Kadota JI; Itoh H
    Chemotherapy; 2018; 63(1):29-34. PubMed ID: 29169153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study.
    Le Clech L; Talarmin JP; Couturier MA; Ianotto JC; Nicol C; Le Calloch R; Dos Santos S; Hutin P; Tandé D; Cogulet V; Berthou C; Guillerm G
    Infect Dis (Lond); 2018 Jul; 50(7):539-549. PubMed ID: 29451055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empirical polymyxin B therapy in febrile neutropenic patients with hematological diseases: A prospective, multicenter, observational clinical study.
    Ma L; Shen J; Jiang H; Qian S; Zhang J; Lan J; Zhou H; Lang W; Mei C; Zhou X; Zhu L; Xu G; Ye L; Hu C; Ren Y; Yang X; Jin J; Ye X; Tong H
    J Infect; 2023 Apr; 86(4):406-409. PubMed ID: 36702310
    [No Abstract]   [Full Text] [Related]  

  • 19. The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies.
    Kaya S; Köksal I; Menteşe A; Sönmez M; Sümer A; Yıldırım SS; Yılmaz G
    Int J Infect Dis; 2013 Nov; 17(11):e1056-9. PubMed ID: 23742830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The "Golden Hour": a capacity-building initiative to decrease life-threating complications related to neutropenic fever in patients with hematologic malignancies in low- and middle-income countries.
    Ornelas-Sánchez M; Nuño-Vázquez L; Loera-Reyna A; Torres-Reyes D; Rivera-Gómez R; Sánchez A; Romano M; González M; Caniza MA; Aristizabal P
    Blood Adv; 2018 Nov; 2(Suppl 1):63-66. PubMed ID: 30504206
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.